Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P170003/S029

Lutonix 018 Drug Coated Balloon PTA Catheter

Lutonix · Decision date Jul 9, 2026

FDA DECISIONP170003/S029

What did the FDA approve?

FDA records P170003/S029 as a supplement to PMA P170003, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Jul 9, 2026.

FDA approval order statement

Approval for a change in the paclitaxel (PTx) active pharmaceutical ingredient (API) supplier.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Cardiovascular
Decision date
Jul 9, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P170003/S029
Regulatory pathway
PMA supplement
Applicant
Lutonix
Product code
PRC
Decision code
APPR
Decision date
Jul 9, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Drug-coated peripheral transluminal angioplasty catheter.

Applicant
Lutonix
Product code
PRC
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P170003/S028 · Related supplement

    Lutonix 018 (Model 9014)

  2. P170003/S029 received

    Application receipt date recorded by FDA.

  3. P170003/S029 · FDA decision

    Real-Time Process

Timeline entries are records held by MedtechLedger for P170003. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P170003

Product / regulatory recordCompanyPathwayDecision dateSource
LutonixPMA supplementSep 4, 2025FDA

Explore the linked device profile

Other records with product code PRC

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Lutonix

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
9409 Science Center Dr., New Hope, MN, 55428

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records